Monoclonal antibodies 2F5 and 4G10 against prostate specific antigen (PSA) complexed to α1-antichymotrypsin

Journal of Urology

Volumn 160, Issue 3 I, 1998, Pages 870-875

  Chen, Zuxiong ^a   Chen, Haibin ^a   Stamey, Thomas A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Monoclonal antibody; Prostate cancer; Prostate specific antigen; PSA ACT complex

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4G10; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0032322541     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62824-6     Document Type: Article

References (35)

1. Prestigiacomo, A. F., Chichibu, K., Kuroe, K. and Stamey, T. A.: Serum PSA assays should be based on PSA-ACT complex to improve the specificity for diagnosing benign prostatic hyperplasia (BPH). J. Urol., 157: 366, Abstract 1431, 1997.
2. Chen, Z., Prestigiacomo, A. and Stanley, T. A.: Purification and characterization of prostate specific antigen (PSA) complexed to α-1-antichymotrypsin: potential referrence material for international standardization of PSA immunoassays. Clin. Chem., 41: 1273, 1995.
3. Lilja, H.: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest., 76: 1899, 1985.
4. Watt, K. W., Lee, P-J., M'Timkulu, T., Chan, W. P. and Loor, R.: Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sxi. USA 83: 3166-3170, 1986.
5. Clements, J. A.: The human kallikrein gene family: a diversity of expression and function. Mol. Cell Endocrinol., 99: C1, 1994.
6. Wang, M. C., Valenzuela, L. A., Murphy, G. P. and Chu, T. M.: Purification of human prostate-specific antigen. Invest. Urol., 17: 159, 1979.
7. Wang, M. C., Papsidero, L. D., Kuriyama, M., Valenzuela, L. A., Murphy, G. P. and Chu, T. M.: Prostate antigen: a new potential marker for prostatic cancer. Prostate, 2: 89, 1981.
8. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317: 909, 1987.
9. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
10. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J., Petros, J. A. and Andriole, G. L.: Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med., 324: 1156, 1991.
11. Armitage, T. G., Cooper, E. H., Newling, D. W., Robinson, M. R. and Appleyard, I.: The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br. J. Urol., 62: 584, 1988.
12. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhekanen, K. and Afthan, O.: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patient with prostate cancer: assay of complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
13. 1-antichymotrypsin. Clin. Chem., 37: 1618, 1991.
14. 1-antichymotrypsin as an indicator of prostate cancer. J. Urol., 150: 100, 1993.
15. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. and Nadler, R. B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 274: 1214, 1995.
16. Prestigiacomo, A. F., Lilja, H., Pettersson, K., Wolfert, R. L. and Stamey, T. A.: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J. Urol., 156: 350, 1996.
17. 1-antichymotrypsin: influence of cancer volume, location and theraputic selection of resistant clones. J. Urol., 152: 1510, 1994.
18. Sensabaugh, G. F. and Blake, E. T.: Seminal plasma protein p30: simplified purification and evidence for identity with prostate-specific antigen. J. Urol., 144: 1523, 1990.
19. Laemmli, U. K.: Cleavage of structure proteins during the assembly of the head of bacteriophage T4. Nature, 227: 680, 1970.
20. Schagger, H. and von Jagow, G.: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem., 166: 368, 1987.
21. Turner, B. M.: The use of alkaline-phosphotase-conjugated second antibody for the visualization of electrophoretically separated proteins recognized by monoclonal antibodies. J. Immunol. Methods, 63: 1, 1983.
22. Harlow, E. and Lane, D.: Antibodies: A Laboratory Manual. Chapter 9, Labeling Antibodies, pp. 319-358, Cold Spring Harbor Laboratory, 1988.
23. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
24. Carter, H. B. and Pearson, J. D.: PSA velocity for diagnosis of early prostate cancer, a new concept. Urol. Clin. N. Am., 20: 665, 1993.
25. Benson, M. C., Whang, I. S., Pantuck, A., Ring, K., Kaplan, S. A., Olsson, C. A. and Cooner, W. H.: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol., 147: 817, 1992.
26. Collins, G. N., Lee, R. J., McKelvie, G. B., Rogers, A. C. N. and Hehir, M.: Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br. J. Urol., 71: 445, 1993.
27. Oesterling, J. E., Jaeobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA, 270: 860, 1993.
28. Stamey, T. A., Barnhill, S. D., Zhang, Z., Madyastha, K. R., Prestigiacomo, A. F., Jones, K. and Chan, D.: Effectiveness of ProstAsure in detecting prostate cancer (PCa) and benign prostatic hyperplasia in men age 50 and older. J. Urol., 155: (Supplement): 504, 1996.
29. Chen, Z., Chen, H. and Stamey, T. A.: Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J. Urol., 157: 2166-2170, 1997.
30. Christensson, A., Laurell, C-B. and Lilja, H.: Enzymatic activity of prostate specific antigen and its reaction with extracellular serine proteinase inhibitors. Eur. J. Biochem., 194: 755, 1990.
31. Chen, Z., Kazuto, K., Prestigiacomo, A. and Stamey, T. A.: Addition of purified prostate specific antigen to serum from female subjects: studies on the relative inhibition by α2-macroglobulin and α1-antichymotrypsin. J. Urol., 156: 1357, 1996.
32. 1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology, 42: 502, 1993.
33. 1-Antichymotrypsin production in benige prostatic hyperplasia. Urology, 43: 427, 1994.
34. 1-antichymotrypsin complex. Clin. Chem., 41: 1480, 1995.
35. Travis, J. and Salvesen, G.: Human plasma proteinase inhibitors. Ann. Rev. Biochem., 52: 655, 1983.